Pharming « Terug naar discussie overzicht

Valeant draadje

353 Posts, Pagina: « 1 2 3 4 5 6 ... 11 12 13 14 15 16 17 18 » | Laatste
[verwijderd]
0
quote:

Diegy schreef op 4 november 2016 16:48:

Ik ben in ieder geval zojuist ingestapt op 19,45. De verkoop zal misschien nabeurs of volgende week bekend worden gemaakt en reken maar dat dat nieuws de koers fors hoger zal zetten.
Zeg het eerlijk voor mij ben je een held.
Sterkte en Toi Toi Toi.

Ruud..

PS hou van een gokje maar dit zo voor het weekend?
voda
0
Valeant boekt verlies

Canadese farmaceut boekt stevige impairment.

(ABM FN-Dow Jones) Valeant Pharmaceuticals International heeft in het afgelopen kwartaal een verlies geleden op een lagere omzet. Dit meldde de Canadese farmaceut dinsdag die ook zijn outlook wijzigde.

In het kwartaal dat eind september eindigde, werd onder aan de streep een verlies geboekt van 1.218 miljoen dollar tegenover een winst van 49,5 miljoen dollar een jaar eerder, een afname die Valeant vooral toeschreef aan een voorziening voor een impairment van 1.049 miljoen dollar, die voornamelijk verband hield met Salix.

Eerder deze maand berichtten media dat Valeant Salix voor 10 miljard dollar van de hand zou willen doen. Salix werd circa anderhalf jaar geleden door Valeant ingelijfd voor 11 miljard dollar, maar het bedrijf gaat gebukt onder een stevige schuldenlast van meer dan 30 miljard dollar.

De aangepaste winst per aandeel daalde van 2,14 naar 1,40 dollar terwijl de omzet op jaarbasis met bijna 300 miljoen dollar afnam. Op kwartaalbasis steeg de omzet van 2,42 miljard dollar in het tweede kwartaal naar 2,48 miljard dollar.

De nieuwe CEO Joseph Papa die in mei Michael Pearson opvolgde, zei in een verklaring "dat het bedrijf vorderingen boekt op weg naar het nieuwe Valeant".

Outlook

Valeant herzag dinsdag de outlook voor heel het boekjaar en rekent nu op een winst per aandeel van tussen de 5,30 en 5,50 dollar tegen eerst tussen de 6,60 en 7,00 dollar en een omzet van tussen de 9,55 en 9,65 miljard dollar tegen een eerdere guidance die lag tussen de 9,9 miljard en 10,1 miljard dollar. Het aangepaste operationele resultaat wordt nu verwacht uit te komen tussen 4,25 miljard en 4,35 miljard dollar waarvoor eerste nog werd gemikt op een range tussen de 4,80 miljard en 4,95 miljard dollar.

Het aandeel Valeant sloot maandag 0,9 procent lager.

Door: ABM Financial News.

info@abmfn.nl

Redactie: +31(0)20 26 28 999

Copyright ABM Financial News. All rights reserved

(END) Dow Jones Newswires
[verwijderd]
0
Valeant Pharmaceuticals To Participate In Healthcare Conferences
Thu November 10, 2016
seekingalpha.com/pr/16663853-valeant-...
LAVAL, Quebec, Nov. 10, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences:

*Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 8:00 a.m. ET at the New York Palace Hotel;
*Guggenheim 4th Annual Boston Healthcare Conference on Tuesday, December 13, 2016 at 11:45 a.m. ET at the Intercontinental Boston; and,
*BMO Prescriptions for Success Healthcare Conference on Wednesday, December 14, 2016 at 1:30 p.m. ET at the InterContinental Barclay Hotel in New York City.

A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL: ir.valeant.com/investor-relations/eve...
[verwijderd]
0
Healthcare ratings roundup - downgrades
www.seekingalpha.com/news/3223470

Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $23 (37% upside) from $81
[verwijderd]
0
NEW YORK, Nov 17 - Two former executives were arrested on Thursday on charges related to the investigation of drugmaker Valeant Pharmaceuticals International Inc's ties to a specialty pharmacy company.
Gary Tanner, a former Valeant executive, and Andrew Davenport, the former chief executive of specialty pharmacy Philidor Rx Services LLC, were charged in a criminal complaint filed in Manhattan federal court, prosecutors said.
The Federal Bureau of Investigation arrested Tanner, 39, and Davenport, 48, on Thursday morning at their residences in Phoenix and Philadelphia, respectively, an agency spokeswoman said. They were expected to appear in court later in the day.
Thursday's complaint accused Tanner of secretly working with Davenport to promote Philidor's business with the goal of consummating a purchase option agreement between Valeant and Philidor.
The agreement resulted in tens of millions of dollars for Davenport personally and close to $10 million in secret kickback payments to Tanner, the complaint said.
Lawyers for the defendants could not be immediately identified. A Valeant representative had no immediate comment.
The development is the latest event to hit Laval, Quebec-based Valeant, whose stock has plunged more than 90 percent since August 2015 amid intense criticism of its drug pricing and business practices and various investigations.
Valeant, whose biggest investor is Bill Ackman's Pershing Square Capital Management, has disclosed receiving subpoenas seeking information related to its ties to Philidor and its accounting treatment for sales by specialty pharmacies.
Valeant shares fell 5 percent, or 88 cents, to $16.99 in New York trading on Thursday morning.
Sursum
0
ir.valeant.com/news-releases/2016/11-...

Valeant Comments On Issued Philidor Criminal Charges
November 17, 2016

LAVAL, Quebec, Nov. 17, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today learned that a criminal complaint was filed in relation to Philidor. Gary Tanner and Andrew Davenport were charged in the matter. The company, former CEO, former CFO, and current executives have not been charged at this time. Gary Tanner ceased to be a Valeant employee on September 13, 2015, and Andrew Davenport has never been an employee of the Company. The counts issued today include allegations that the charged parties engaged in actions to defraud Valeant as a company. Valeant continues to cooperate with all relevant authorities in this matter.
Masiquodo
0
Ze maken Valeant wel echt kapot zo in het nieuws.
Denk dat er nog meer gaat komen en dat 1 dollar voor het aandeel nog hoog is.
Dit wordt Pharming 2.0
DeZwarteRidder
0
Takeda Pharmaceutical Co Ltd's (4502.T) negotiations to acquire Valeant Pharmaceuticals International Inc's (VRX.TO) Salix stomach-drug business have stalled over price disagreements, people familiar with the matter said on Wednesday.

Shares of Valeant were down more than 8 percent at $15.71 on Wednesday after the Wall Street Journal reported that the talks had broken down. A deal for Salix would help Valeant trim the large debt pile it accumulated through aggressive acquisitions.

Valeant had said on Nov. 1 that it was in talks with several parties about selling Salix. But on Tuesday, the Canadian company said it was expanding its sales force for Salix's key product, Xifaxin, among other drugs, suggesting plans to keep the business for the long term.

The sources asked not to be identified because the negotiations are confidential. Valeant and Takeda declined to comment.

Previous reports said that a sale of Salix could raise as much as $10 billion for Valeant, which has been struggling under a roughly $30 billion debt load after repeatedly slashing earnings expectations.

Valeant's stock has declined more than 90 percent in the past year, erasing nearly $90 billion in market capitalization, over disclosures that it secretly worked with a specialty pharmacy to boost sales of its medicines. The company is the subject of multiple investigations by federal agencies and state prosecutors.

Salix Pharmaceuticals makes treatments for disorders such as irritable bowel syndrome and diarrhea.

Valeant's new chief executive officer, Joseph Papa, has committed to selling around $8 billion in non-core assets to help pay down debt that it accumulated over the course of a series of large acquisitions.

Takeda tried earlier this year to buy Salix as part of a joint bid with private equity firm TPG, a few weeks before Papa took over as CEO. But Valeant's board rejected the offer as it wanted to give Papa time to map out a course for the company.
[verwijderd]
0

By Jonathan D. Rockoff and David Benoit
Valeant Pharmaceuticals International Inc.'s talks to sell a stomach-drug business to Japan's Takeda Pharmaceutical Co. for roughly $10 billion have broken down amid last-minute disagreements over price and other matters, according to people familiar with the matter.
Though the talks could still be revived, Valeant is now focused on building the business, Salix Pharmaceuticals, rather than selling it, the people said.
The development represents another setback for a company that has been plagued by an accounting scandal, the departure of its top executives and a plummeting share price. As of Tuesday's close, Valeant shares had fallen 80% in the past year.
Valeant is now moving ahead with plans to build the sales force for Salix's crown jewel, the irritable-bowel drug Xifaxan. Valeant announced the "significant" expansion in a news release Tuesday.
Valeant's shares, which had already been sagging after Tuesday's announcement, fell further after The Wall Street Journal reported on the breakdown and were recently off more than 7%, at $15.92.
One of the 11th-hour disputes was over the sum of an agreement, which Takeda sought to reduce, according to people familiar with the matter.
Takeda, a big Japanese drugmaker that has prioritized stomach drugs, had approached the beleaguered Canadian pharmaceutical company about purchasing Salix and the sides been near a deal that would have included $8.5 billion in cash plus royalty payments, the Journal had reported earlier in November.
That report sent Valeant's stock up 34%, but the gains have evaporated in recent weeks after a disappointing third quarter and another cut to its earnings guidance.
Valeant is in the process of trying to sell several assets in its portfolio, which had been built largely through acquisitions, to pay down roughly $30 billion in debt. It is also exploring selling a surgical-equipment business that could fetch $2.5 billion, the Journal has reported.
Valeant has said it hadn't intended to sell Salix, which it only bought last year and considers a core asset, but had to listen when a prospective bidder seemed willing to pay a good price.
Some inside Valeant have argued against selling the unit because it is a potential source of significant sales growth, one of the people said.
A sale would help Valeant pay off roughly $12 billion in bank debt, which is the most pressing concern for investors who fear a collapse in the company's earnings could put it at risk. And a purchase would help Takeda boost its stomach-drugs franchise.
Takeda has sought several times to acquire Salix and Xifaxan, which Valeant had predicted could have $1 billion in sales this year. Takeda was a bidder for the company when Valeant won an auction for Salix in 2015, and earlier this year approached Valeant with a partner about buying the whole company, the Journal has reported.
Xifaxan sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan.
Valeant hopes an expanded sales force will boost Xifaxan sales by targeting the primary-care doctors who often treat such conditions. But the company attributed its lower its earnings guidance in part to the expense of increasing its sales force.
Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com and David Benoit at david.benoit@wsj.com
(END) Dow Jones Newswires
December 01, 2016 02:48 ET (07:48 GMT)
© 2016 Dow Jones & Company, Inc.

AAND TAKEDA PHARMACEUTICAL DE NOT
JP3463000004
AAND VALEANT PHARMA INTERN AM NOT
CA91911K1021
TAKEDA PHARMACEUTICAL CO LTD SPON ADR EA REPR 0.5 ORD
US8740602052
Chiddix
0
Meltdown koers Valeant. Van $270 naar dieptepunt iets onder de $14. Thans $15. Om het circus draaiende te houden toen de koers in de $200 noteerde, werden de prijzen van medicijnen van Valeant in de VS omhoog geschroefd , wat zelfs de aandacht trok van Hillary Clinton. De mooie cijfers in 2014 kwamen vrijwel uitsluitend door prijsverhogingen in de VS. Valeant is het middelpunt geworden van overheidsinstanties VS en de SEC. Met donderend geraas is de koers in een kort tijdsbestek ingestort. Om het schip drijvende te houden , werd Salix in de verkoop gezet. Heeft nog niet geleid tot het gewenste resultaat. Dit bedrijf gaat tot het uiterste om hun inkomsten er beter uit te laten zien dan ze zijn. EPS adjusted is een toverwoord bij Valeant. Het Nederlandse navigatiebedrijf TT schermt ook met zulke begrippen.
Omnius
0
Ze hadden nog beter even kunnen wachten om Ruconest terug te kopen.. binnenkort executieverkoop bij Valeant...
[verwijderd]
0
Dat denk ik niet... de naam Valeant is besmet... wegwezen daar...

Binnenkort rechtzaak waar heel amerika alles via de media besmeurt krijgt... mediageile advocaat erop geklapt.

Vanaf morgen (vanmiddag?) weg en handen vrij om zelf te sturen.

Nogmaals: perfect timing zo!

[verwijderd]
1
quote:

IlIIIlIIIlIIIIIIlllllllIIII schreef op 7 december 2016 16:05:

Dat denk ik niet... de naam Valeant is besmet... wegwezen daar...

Binnenkort rechtzaak waar heel amerika alles via de media besmeurt krijgt... mediageile advocaat erop geklapt.

Vanaf morgen (vanmiddag?) weg en handen vrij om zelf te sturen.

Nogmaals: perfect timing zo!

Mijn gedachte. Prima gedaan door S. de Vries en R. Wright.
[verwijderd]
0
Zo is het... ze hebben een enorme berg puin moeten ruimen wat ze zo in de schoot geworpen kregen. En nu zijn zij aan zet.

Ik vind het knap...

en nu wilde ik nog wat zeggen...maar wat was dat ook alweer?...

DeZwarteRidder
0
Valeant Pharmaceuticals: We Were Wrong, Morgan Stanley Says
By Ben Levisohn

Valeant Pharmaceuticals International (VRX) has elected not to sell its Salix business–and that’s left Morgan Stanley analyst David Risinger and team with no choice but to cut the stock to Equal Weight from Overweight. They explain why:

Since our upgrade in August, our investment thesis that management would stabilize the business and execute accelerated deleveraging via divestitures has been wrong. When we upgraded Valeant shares from EW to OW on August 17, 2016, we expected business stabilization and material divestitures. Neither has happened to date. Additionally, Valeant announced the departure of certain executives on Dec. 12 (see Executive departures an area of concern), and we no longer believe that shares can outperform. Although we have been disappointed in the progress, divestitures could still occur at any time, and management could enhance business performance.

Risinger also lowered his price target on Valeant to $17 to “reflect the uncertainty.”

Shares of Valeant Pharmaceuticals International have dropped 5.9% to $13.29.

Valeant Pharmaceuticals International (VRX) has elected not to sell its Salix business–and that’s left Morgan Stanley analyst David Risinger and team with no choice but to cut the stock to Equal Weight from Overweight. They explain why:

Since our upgrade in August, our investment thesis that management would stabilize the business and execute accelerated deleveraging via divestitures has been wrong. When we upgraded Valeant shares from EW to OW on August 17, 2016, we expected business stabilization and material divestitures. Neither has happened to date. Additionally, Valeant announced the departure of certain executives on Dec. 12 (see Executive departures an area of concern), and we no longer believe that shares can outperform. Although we have been disappointed in the progress, divestitures could still occur at any time, and management could enhance business performance.

Risinger also lowered his price target on Valeant to $17 to “reflect the uncertainty.”

Shares of Valeant Pharmaceuticals International have dropped 5.9% to $13.29.

December 15, 2016, 9:57 A.M. ET
353 Posts, Pagina: « 1 2 3 4 5 6 ... 11 12 13 14 15 16 17 18 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 19 apr 2024 17:35
Koers 0,881
Verschil +0,013 (+1,50%)
Hoog 0,889
Laag 0,869
Volume 8.926.686
Volume gemiddeld 6.927.541
Volume gisteren 37.599.271

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront